COVID UPDATES. TIME TO DECIDE ABOUT SPREADING COVID

[Analin]

Convenient how with the new surge, the provision for covid pay has been done away with. Someone in my home tested positive Sunday, and my job says don't come in and don't worry about the pay, we got this! An email today informed me otherwise. NO PAY, NO WAY! Come back next week, maybe. Who cares that I've tested negative twice this week.

I've never had covid or asked for covid pay, until this current situation and now they change the rules. I can't spread something I don't have. What is this fuckery?

[IceWizard]

[Charon]

exactly.

[Analin]

---

Oof it took me an hour to figure out how to post a picture here.. still blurry and too big. Bear w me, I tried HAHA

[IceWizard]

>https://picresize.com

Works for me

Ice

[Analin]

I'll keep practicing lol

[Charon]

the flu has combined with the omnicron variant. according to them.

and so hospitals r allegedly getting full.

and, cuz me sister called whilst i was reading my phone news, it was lost but they have a name for the new variant they are saying is next.

maybe good ole dr. faux ci will know. many vaccinated and boosted people are getting the omnicron. some say once vaccinated, they get the covid. be careful. it is everywhere again and the flights i hear overhead at all hours does not give me comfort. and psaki said they wont be staying here. oh good. just long enuff to give us the illnesses?

[IceWizard]

I heard that...
They call it "FluRona" I believe I saw...

Unreal...
Ice

[Charon]

hxxps://www.msn.com/en-us/health/medical/what-we-know-so-far-about-ihu-covid-19-variant-symptoms/ar-AAStmXZ?ocid=winp1taskbar

Deseret News
Deseret News
What we know so far about IHU COVID-19 variant symptoms
Herb Scribner - Yesterday 5:00 PM

Follow
|

81




What we know so far about IHU COVID-19 variant symptoms
© Alex Cochran
What we know so far about IHU COVID-19 variant symptoms
Scientists and experts in France are keeping their eyes on the new IHU COVID-19 variant that has emerged in recent days.

The new variant — called the IHU variant because it was found by academics at the institute IHU Mediterranee Infection — has been linked to 12 cases near Marseilles, France, according to Business Insider.
The variant — with the scientific name B.1.640.2 — reportedly has 46 mutations in an “atypical combination,” according to researchers.
However, the IHU variant has not been found in countries outside of France. It has not been labeled a variant of concern by the World Health Organization, either.

And just so we’re clear, the variant would be called the “pi variant” if the WHO did deem it one of concern since pi is the next Greek alphabet letter after omicron. WHO uses the Greek alphabet to name the variants.
What are the symptoms of the IHU variant? Per Business Insider, the variant appears to be more transmissible, which means it could infect more people. Otherwise, it’s unclear if the variant has specific symptoms other than traditional COVID-19 symptoms.

News of the IHU variant drummed up this week after a traveler in France tested positive for a COVID-19 variant. But this variant may have been seen before. In November, I reported for the Deseret News that 24 people in a French school in October 2021 were infected with a variant called B.1.X or B.1.640, which appears to be the same variant.

At the time, the France variant struggled to rise about the delta variant, which was spreading far and wide throughout the world.
A fast-spreading variant like delta or omicron will often overtake smaller variants since it will infect more people and cause immunity. stopping other variants from spreading.

We’ve seen this happen with mu and lambda, which were both dominated by delta.
Eric Feigl-Ding, a well-known epidemiologist, said on Twitter that variants pop up all the time. So more research will be needed to find out more about the IHU variant.

“There are scores of new variants discovered all the time, but it does not necessarily mean they will be more dangerous. What makes a variant more well-known and dangerous is its ability to multiply because of the number of mutations it has in relation to the original virus.”
He added, “It remains to be seen in which category this new variant will fall.”

[Charon]

hxxps://www.nytimes.com/2022/01/05/health/covid-rapid-test-omicron-detection.html?fbclid=IwAR0leOEGEwbnC4RWzOmmV-Tu6QscAfzerA1w5gDgR7taHEnjaB_y70wSpG4

Emerging Data Raise Questions About Antigen Tests and Nasal Swabs
A new study adds to evidence that common rapid tests may fail to detect some Omicron cases in the first days of infection.




Rapid antigen Covid test kits at Miami International Airport on Tuesday.
Rapid antigen Covid test kits at Miami International Airport on Tuesday.Credit...Saul Martinez for The New York Times
By Emily Anthes and Christina Jewett
Jan. 5, 2022
A small, new real-world study suggests that two widely used at-home antigen tests, the Abbott BinaxNOW and Quidel QuickVue, may fail to detect some Omicron infections even when people are carrying high levels of the coronavirus.

The study, which has not yet been peer-reviewed, focused on 30 people infected with the virus at five workplaces that experienced what were most likely outbreaks of the Omicron variant in December. The people received both saliva-based P.C.R. tests and rapid antigen tests using nasal swabs.

It took three days, on average, for people to test positive on a rapid antigen test after their first positive P.C.R. result. In four cases, people transmitted the virus to others while the rapid test showed the negative result, according to the study, which was conducted by several members of the Covid-19 Sports and Society Working Group.

It is not clear whether the infections were missed because the antigen tests are inherently less sensitive to Omicron or because saliva tests may be better at detecting the new variant.

ADVERTISEMENT

Continue reading the main story

But the results are consistent with other preliminary evidence that the at-home tests that many Americans have come to rely on — at least as currently administered, with a nasal swab — may fail to detect some Omicron cases in the first days of infection.

The researchers said they shared their results with federal officials — including at the White House, the Food and Drug Administration and the Centers for Disease Control and Prevention — in real-time, as the outbreaks were occurring last month.

Dig deeper into the moment.
Special offer: Subscribe for $1 a week.
“They’re aware that there are flaws with antigen testing,” said Dr. Robby Sikka, an author of the study and chair of the working group.

The study comes a week after the Food and Drug Administration released its own update on the effectiveness of the rapid antigen tests. “Early data suggests that antigen tests do detect the Omicron variant but may have reduced sensitivity,” the agency said.

Many of the studies are early and small, and much more data is needed. The tests, which can deliver results at home in minutes, remain an important public health tool, and positive results are especially likely to be informative, many scientists said. (The wait for P.C.R. results can stretch for days.)



Continue reading the main story

“The message is not that we should stop using these tests,” said Isabella Eckerle, a clinical virologist at the University of Geneva in Switzerland.

But people should be cautious about interpreting negative results, especially when they have symptoms or believe they may have been exposed to the virus.

“It’s not a ticket that allows you to go back to normal or to drop any other measures,” Dr. Eckerle said.

Assessing sensitivity

Image
Vaccinations and testing at a subway station in Times Square in Manhattan last month.
Vaccinations and testing at a subway station in Times Square in Manhattan last month.Credit...Sarah Blesener for The New York Times
Antigen tests are designed to detect proteins on the surface of the coronavirus. If mutations in the virus change the structure of these proteins, antigen tests might fail to detect the variant.

The Omicron variant has about 50 mutations, including more than 30 on the spike protein alone. Most rapid antigen tests are designed to detect more stable targets, which are far less mutated in Omicron.

Still, even minor-seeming mutations can affect a virus’s surface proteins, “sometimes in non-obvious ways,” said John Moore, a virologist at Weill Cornell Medicine. “Only experimental data can determine whether there is an impact or not.”

ADVERTISEMENT

Continue reading the main story

The F.D.A. in September told makers of rapid tests that they would be required to continue to test their products as new variants emerged, and, if asked, to share those results with the agency.

Many companies have announced that their tests can detect Omicron, and several independent scientists said that they believed the tests should be capable of recognizing the variant, especially when present at high levels. But a few new studies raise questions about the tests’ sensitivity.

The F.D.A.’s update stemmed from an evaluation it is doing with the National Institutes of Health, said Bruce Tromberg, director of the National Institute of Biomedical Imaging and Bioengineering. The scientists evaluated the antigen tests using pooled samples of nasal mucus collected from multiple people with Omicron, as well as similar pooled samples from Delta patients.

The Coronavirus Pandemic: Latest Updates
Updated
Jan. 6, 2022, 5:52 p.m. ET1 hour ago
1 hour ago
The Mayo Clinic will dismiss 1 percent of its staff for missing vaccine deadline.
New York will send officers to subways in bid to lure more riders back.
Portugal eases pandemic restrictions on those with booster shots.
Scientists then diluted each of these pooled samples until the antigen tests no longer detected the virus. The tests were able to detect more dilute solutions of Delta samples than Omicron samples, suggesting that the tests may be less sensitive to the new variant, Dr. Tromberg said. Still, he added, in real-world settings, “it may not translate into any different sensitivity.”

An F.D.A. spokeswoman, Stephanie Caccomo, said last week that studies were underway “to confirm the reason for the apparent decreased sensitivity.”

“Once that is known,” she said, “adjustments to existing tests can be undertaken by each developer with support from the F.D.A., if appropriate.”

The F.D.A. update was not the first hint that some antigen tests may be less sensitive to Omicron. Dr. Eckerle and her colleagues recently evaluated the performance of seven antigen tests against samples of the virus grown from specimens taken from people infected with Omicron. Overall, the researchers found, the tests were less sensitive to Omicron than to previous variants.

“They missed samples with infectious virus, and they missed samples that had quite a decent viral load,” Dr. Eckerle said. The work has not yet been published in a scientific journal.

ADVERTISEMENT

Continue reading the main story

But there was also vast variability in the performance of the different tests, most of which are not available in the United States. And an Australian study, which examined a mostly different collection of antigen tests, found that the tests had a similar sensitivity to Omicron and Delta.

More data are needed, experts said.

“Each test is going to have to be evaluated independently any time there’s a new variant,” said David O’Connor, a virologist at the University of Wisconsin, Madison who urged people not to stop using rapid tests. “And that takes some time.”

Swabbing sites
The new study focused on five New York and California workplaces that had virus outbreaks in December. In 29 of 30 people, samples of the virus produced a telltale genetic pattern on P.C.R. tests, suggesting that these individuals were most likely infected with Omicron.

Each participant took P.C.R. and antigen tests daily over a period of up to 10 days. The discordant results overwhelmingly came during the first three days of infection.

The Coronavirus Pandemic: Key Things to Know
Card 1 of 6
The global surge. The coronavirus is spreading faster than ever, but it appears that Omicron is milder than previous variants. Still, the latest surge in cases is causing hospitalizations in the U.S. to rise and lifesaving treatments to be rationed.

Boosters. The C.D.C. endorsed booster shots of the Pfizer vaccine for children ages 12 to 17, citing rising infections in teens and young adults. The agency also said being “up to date” on the vaccine now includes having a booster, though it was not yet changing its definition of “full vaccination.”

Testing. A new study suggests that two widely used at-home antigen tests may fail to detect some Omicron cases in the first days of infection. The study comes as a White House official said that the cost of rapid at-home tests will be reimbursed by insurers starting next week.

U.S. strategy. Six advisers to President Biden’s transition team urged him to adopt a new pandemic strategy — one that is geared to the “new normal” of living with the virus indefinitely. Meanwhile, the C.D.C. is facing criticism for repeatedly failing to explain its policy decisions to the public.

Around the world. In China, a city of 13 million is locked down over a handful of cases, leading to questions over how long the country’s zero-Covid strategy can last. In France, President Emmanuel Macron drew criticism for saying the government should make life miserable for the unvaccinated.

Staying safe. Worried about spreading Covid? Keep yourself and others safe by following some basic guidance on when to test and how to use at-home virus tests (if you can find them). Here is what to do if you test positive for the coronavirus.

“A negative result may not actually be a negative result,” said Anne Wyllie, a microbiologist at the Yale School of Public Health and an author of the new study. “People should not ignore high risk exposures. They should not ignore symptoms.”

The study’s other authors are Blythe Adamson, the founder of Infectious Economics, a public health consulting company, and Dr. Prem Premsrirut, the chief executive of Mirimus Laboratories, which offers saliva-based P.C.R. testing.

An Abbott spokesman, John Koval, said on Wednesday that the finding that a P.C.R. test is more sensitive is “not new.”

ADVERTISEMENT

Continue reading the main story

“Due to immediate turnaround time, frequent rapid antigen testing does slow transmission — and with a highly infectious variant frequent testing is needed, which is not realistic with P.C.R.,” he wrote in an email.

Quidel’s president, Douglas Bryant, said in a statement that the company performed recent testing using samples from South Africa and confirmed that its rapid tests are detecting the Omicron variant.

A company spokesperson also said that it was not surprising that saliva-based P.C.R. tests detected the virus before nasal swabs did, if the study accurately concluded that viral load peaks first in saliva. The company noted that its rapid tests only have F.D.A. clearance to collect nasal swab specimens.

In a smaller analysis, of five participants who took both nasal and saliva-based P.C.R. tests, the researchers found that the levels of virus peaked in saliva samples a day or two before they peaked in samples collected from the nose.

Those findings are consistent with a recent report from South Africa, which has not yet been reviewed by experts. The researchers found that P.C.R. tests picked up a higher share of Omicron infections when saliva samples — produced by the rubbing of a swab inside the cheeks, around the gums and tongue — were used instead of nasal samples. The reverse was true for Delta.

“Ideally, until we can directly compare the relative sensitivity of the antigen tests, my suggestion would be to test both sites,” Diana Hardie, a clinical virologist at the University of Cape Town, who led the research, said in an email.

One possible explanation for the findings is that Omicron replicates faster or earlier in the throat and mouth than in the nose.

ADVERTISEMENT

Continue reading the main story

“While we’ll have to wait to see if the science bears out, that might be an indicator that that’s where the virus is growing first,” said Gigi Gronvall, an immunologist and testing expert at Johns Hopkins Bloomberg School of Public Health. “So if you’re going to look for the virus, which is what the tests do, then you may find more of it faster in the throat swab over the nose.”

Anecdotal reports have also emerged that some people who tested negative on antigen tests when they swabbed inside their noses received a positive result when they instead swabbed the back of their throats.

“There’s a lot of chatter around this,” said Nathan Grubaugh, a virologist at the Yale School of Public Health. “Obviously, that warrants further investigation.”

Some tests available in Britain call for swabbing both the nose and the throat, but the antigen tests available in the United States are not authorized for the collection of saliva or samples from the throat.

Omicron’s rapid replication also means that there is a narrower window to catch the virus before it begins spreading, and that people may need to test themselves sooner after a potential exposure and as close as possible to an upcoming gathering or event, experts said. They may also need to test themselves more frequently overall, a particular challenge when the tests are in short supply.

People who may have been exposed to the virus should take at least two antigen tests over the course of about two days, experts said.

More News About Omicron

ok, in me own defense, i do realize when the post has writing about copy here, or doubles a line, but i aint got the time to edit further. its not the same as Lets Go Brandon stating: end of quote, as he did today was it?